ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2007
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.
Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 92 citations in OpenAlex.
- Mechanisms and Manifestations of Ligand Bias in Signaling: Focus on Receptor Tyrosine Kinases.Chemical reviews · 2026Review
- Insight into the inhibitory activity of mangiferin and Silybin against HER2 and EGFR using theoretical and experimental approaches.Scientific reports · 2025Article
- Mechanistic Insights into Membrane Protein Clustering Revealed by Visualizing EGFR Secretion.Research (Washington, D.C.) · 2022Article
- Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.BioMed research international · 2022Review
- The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.Pharmacological reviews · 2022Review
- Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.Journal of computer-aided molecular design · 2020Article
- Current Approaches in NSCLC Targeting K-RAS and EGFR.International journal of molecular sciences · 2019Review
- Filamin A regulates EGFR/ERK/Akt signaling and affects colorectal cancer cell growth and migration.Molecular medicine reports · 2019Article
- Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.Journal of translational medicine · 2019Article
- Boehmenan, a Lignan From the Chinese Medicinal Plant Clematis armandii, Inhibits A431 Cell Growth via Blocking p70S6/S6 Kinase Pathway.Integrative cancer therapies · 2017Article
- Quantification of growth factor signaling and pathway cross talk by live-cell imaging.American journal of physiology. Cell physiology · 2017Article
- pH dependence of ligand-induced human epidermal growth factor receptor activation investigated by molecular dynamics simulations.Journal of molecular modeling · 2016Article
- Mapping growth-factor-modulated Akt signaling dynamics.Journal of cell science · 2016Article
- Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab.Oncotarget · 2016Article
- Role of ErbB Receptors in Cancer Cell Migration and Invasion.Frontiers in pharmacology · 2015Review
- EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer.Molecular cancer · 2014Article
- Membrane interaction of bound ligands contributes to the negative binding cooperativity of the EGF receptor.PLoS computational biology · 2014Article
- A brain-specific Grb2-associated regulator of extracellular signal-regulated kinase (Erk)/mitogen-activated protein kinase (MAPK) (GAREM) subtype, GAREM2, contributes to neurite outgrowth of neuroblastoma cells by regulating Erk signaling.The Journal of biological chemistry · 2013Article
- Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.Journal of cancer research and therapeutic oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Signaling by the Epidermal Growth Factor Receptor (EGFR) and related ErbB family receptor tyrosine kinases can be deregulated in human malignancies as the result of mutations in the genes that encode these receptors. The recent identification of EGFR mutations that correlate with sensitivity and resistance to EGFR tyrosine kinase inhibitors in lung and colon tumors has renewed interest in such activating mutations. Here we review current models for ligand stimulation of receptor dimerization and for activation of receptor signaling by receptor dimerization. In the context of these models, we discuss ErbB receptor mutations that affect ligand binding and those that cause constitutive receptor phosphorylation and signaling as a result of constitutive receptor dimerization. We discuss mutations in the cytoplasmic regions that affect enzymatic activity, substrate specificity and coupling to effectors and downstream signaling pathways. Finally, we discuss how emergent mechanisms of ErbB receptor mutational activation could impact the search for clinically relevant ErbB receptor mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.